Hyderabad: Clinical trials on for Covaxin for children
Several research activities are being carried out to study Variants of Concern and assess their suitability for follow-up booster doses, the company said here on Tuesday.
Hyderabad: Bharat Biotech is carrying out additional clinical trials of its vaccine – Covaxin to establish safety and efficacy in children between two and 18 years of age in India. Further, a clinical trial to determine the safety and immunogenicity of a booster dose was also in process.
Several research activities are being carried out to study Variants of Concern and assess their suitability for follow-up booster doses, the company said here on Tuesday.
Covaxin has now received Emergency Use Authorizations (EUA) in 16 countries including, Brazil, India, Philippines, Iran, Mexico, etc. In nearly 50 other countries, teh EUA was in process. Bharat Biotech is in discussions with WHO to obtain Emergency Use Listing for Covaxin. The product has been exported to several countries, with additional requests for supplies being received.
Bharat Biotech has established Covaxin manufacturing at four facilities within India, and further expansion is in process to reach an annualized capacity of one billion doses by the end of 2021. Technology transfer activities are in progress to companies in the United States and other countries, the company said.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
